What topics does this cannabis study cover?

This study covers research on: Mental Health, THC.

Where was this research published?

Published in Asian journal of psychiatry on June 1, 2026.

Symptoms fade, but recovery is far more complicated

Q: What did this Review find?

Cannabis-induced psychosis accounts for **12-35% of first-episode psychosis cases globally**, yet the long-term recovery picture is far more complex than commonly assumed. This comprehensive review of 33 studies involving **18,117 participants** found a critical disconnect between what appears on th

Multi-dimensional recovery trajectories in cannabis-induced psychosis: A systematic review examining symptomatic, functional, cognitive, and subjective outcomes.

Asian journal of psychiatry • June 1, 2026 • Review • Moderately Relevant

🤖

AI Summary

Cannabis-induced psychosis accounts for 12-35% of first-episode psychosis cases globally, yet the long-term recovery picture is far more complex than commonly assumed. This comprehensive review of 33 studies involving 18,117 participants found a critical disconnect between what appears on the surface and what's happening beneath. While 50-70% of patients achieved symptomatic remission within 6 months, functional recovery—the ability to work, maintain relationships, and manage daily life—showed substantial heterogeneity, with many patients continuing to struggle despite symptom improvement. This symptom-function dissociation reveals that simply feeling better doesn't necessarily mean getting better in practical, meaningful ways.

The most striking finding relates to continued cannabis use, which emerged as the strongest predictor of poor outcomes across all recovery dimensions, with persistence rates of 35-65% among continued users. Conversely, those who achieved cannabis cessation demonstrated significant functional recovery with an effect size of 1.26—a substantial clinical benefit. However, cognitive outcomes remained heterogeneous and poorly understood, and subjective experiences (how patients feel about their recovery) were assessed in only 38% of studies, revealing a major gap in our understanding of what truly matters to patients.

The review highlights a fundamental problem with how we define "favorable prognosis" in cannabis-induced psychosis: the field's narrative is built almost exclusively on symptom resolution, overlooking functional, cognitive, and subjective dimensions of recovery. Only 15% of studies used person-centered trajectory modeling, which identified five distinct recovery profiles, suggesting that one-size-fits-all assumptions about cannabis-induced psychosis are misleading. This research calls for a paradigm shift—moving beyond symptomatic remission toward comprehensive interventions that address practical functioning, cognitive health, and the lived experiences of patients navigating recovery.

📄 Original Abstract

Cannabis-induced psychotic disorders represent 12-35% of first-episode psychosis presentations globally. Traditional clinical wisdom holds these conditions carry favorable prognosis based on rapid symptomatic improvement, yet this narrative rests almost exclusively on symptomatic outcomes, overlooking functional, cognitive, and subjective recovery dimensions. To systematically review multi-dimensional recovery trajectories following cannabis-induced or cannabis-associated first-episode psychosis, characterizing patterns of concordance and discordance across outcome domains and identifying predictors of recovery profiles. We searched five databases (PubMed/MEDLINE, PsycINFO, Embase, Web of Science, Cochrane Library) from inception to December 2024. longitudinal studies (≥6 months follow-up) assessing ≥ 2 outcome domains among symptomatic, functional, cognitive, and subjective recovery in cannabis-induced first-episode psychosis. Two independent reviewers screened studies and assessed quality using Newcastle-Ottawa Scale. Data were synthesized narratively. Thirty-three studies encompassing 18,117 participants were included (mean follow-up 24 months, range 6 months-10 years). While 50-70% achieved symptomatic remission within 6 months, functional recovery revealed substantial heterogeneity and frequent symptom-function dissociation. Continued cannabis use emerged as strongest predictor of poor outcomes across domains (persistence rates 35-65%), though cessation demonstrated significant benefits (functional recovery effect size 1.26). Cognitive findings were heterogeneous, and subjective outcomes remained poorly characterized (assessed in only 38% of studies). Only 15% of studies employed person-centered trajectory modeling, revealing five distinct recovery profiles. Symptomatic improvement frequently fails to translate into functional recovery following cannabis-induced psychosis. The field's understanding of "favorable prognosis" inadequately captures comprehensive multi-dimensional recovery, necessitating interventions targeting functional, cognitive, and subjective domains beyond symptomatic remission.

Paper Type

📚 Review

Publication

Journal: Asian journal of psychiatry
Published: June 1, 2026
PMID: 41980405
DOI: 10.1016/j.ajp.2026.104975

Authors (5)

Valerio Ricci University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole, 10, Orbassano 10043, Italy. Electronic address: valerio.ricci@unito.it.
Alessandro Sarni University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole, 10, Orbassano 10043, Italy; Department of Neurosciences "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10126, Italy.
Marialuigia Barresi University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole, 10, Orbassano 10043, Italy; Department of Neurosciences "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10126, Italy.
Lorenzo Remondino University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole, 10, Orbassano 10043, Italy; Department of Neurosciences "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10126, Italy.
Giuseppe Maina University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole, 10, Orbassano 10043, Italy; Department of Neurosciences "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10126, Italy.